Save

Nicox enters agreement to help promote Sjögren’s syndrome test

ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on . Please provide your email address to receive an email when new articles are posted on Subscribe ADDED TO EMAIL ALERTS You've successfully added to your alerts. You will receive an email when new content is published.



Click Here to Manage Email Alerts You've successfully added to your alerts. You will receive an email when new content is published.



Click Here to Manage Email Alerts



Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.



Back to Healio

Nicox has entered into an exclusive agreement with Immco Diagnostics to help promote Immco’s proprietary laboratory test for early detection and diagnosis of Sjögren’s syndrome, according to a press release.

The test, developed at the University of Buffalo and Immco Diagnostics, uses three novel biomarkers (SP-1, CA-6 and PSP) along with traditional markers (ANA, Ro, La and RF) for early detection with high sensitivity.

“Rheumatologists have been challenged with the management of late-stage Sjögren’s patients for years with mixed results,” Julian L. Ambrus Jr., MD, from the University of Buffalo, said in a press release. “The problem has always been that there was no effective method to easily diagnose these patients earlier in the disease process.”

Nicox will market the test to eye care practitioners in the United States, Canada, Puerto Rico and Mexico and receive a majority share of revenue that comes from practitioners. Immco will administer the test in Buffalo, N.Y., and manage regulatory activities and reimbursement.

The test was approved in the U.S. this year. It is expected to launch commercially by Nicox in the second half of the year.